Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer

Human Steroid Biosynthesis for the Oncologist

(2016) Mary Louise Auchus et al.   JOURNAL OF INVESTIGATIVE MEDICINE

Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302)

(2014) Dana E. Rathkopf et al.   EUROPEAN UROLOGY

Dehydroepiandrosterone Sulfate (DHEAS) Stimulates the First Step in the Biosynthesis of Steroid Hormones

(2014) Jens Neunzig et al.   PLoS One

Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness–a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer

(2013) Marcelo Madeira et al.   BMC CANCER

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

(2012) Karim Fizazi et al.   LANCET ONCOLOGY

Androgen Receptor Expression and Breast Cancer Survival in Postmenopausal Women

(2011) R. Hu et al.   CLINICAL CANCER RESEARCH

Expression of androgen receptors in primary breast cancer

(2009) S. Park et al.   ANNALS OF ONCOLOGY

Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells

(2009) Francesca De Amicis et al.   BREAST CANCER RESEARCH AND TREATMENT

Challenges to defining a role for progesterone in breast cancer

(2008) C LANGE   STEROIDS